Russian investors, interested in pharmaceutical and medical assets, acquiring more targets in Western Europe more and more Russian investors and Pharma companies are interested in Western European healthcare and Pharma / OTC targets. Nowadays the CIS and CEE pharmaceutical markets develop very well, mostly above 15-17%. However the markets are still dominated by more than 80% of imported products from Western Europe, Asia and the U.S. will this change? Will what change? We at Chameleon Pharma consulting notice that more and more Russian, Ukrainian, Polish and Kazak investors and Pharma cooperations are interested to acquire healthcare or pharmaceutical products and companies in Western Europe. Some players like the Slovenian KRKA group have already made a move towards ‘west’ some years ago. They bought the German pharmaceutical company TAD in the North of the country.
Others Russian investors are currently on “a pharmaceutical & medical company target shopping tour” in Europe. However Russian investors seam to be “slow movers” to invest into medical or pharmaceutical companies in Europe. This may happen due to the lack of market knowledge or other reasons. “Howerver find investments in Europe could definitely bring innovative products and techniques to the Russian healthcare market and investors could benefit from long term stable profits, say Reiner Christensen, the CEO of Chameleon Pharma consulting. “We, Chameleon Pharma consulting, had many interesting discussions with Russian investors during last months but Russian players need to be quicker in the diligence execution”, says Andreas Masel, the Pharma of Chameleon Pharma consulting veteran. US and Asian investors seem to be faster so far to decide on innovative healthcare investments in Europe and thus earn the advantages from these smart steps. Andreas Masel adds, “I would recommend Russian investors, interested in pharmaceutical and medical assets, balancing their portfolio and acquiring more targets in Western Europe. This could also bring good technologies to the CIS & CEE markets.”